

Probiotics and non-intestinal infectious conditions

M. de Vrese* and J. Schrezenmeir

Federal Dairy Research Centre, Department of Physiology and Biochemistry of Nutrition, Hermann-Weigmann-Straße 1, D-24103 Kiel, Germany

Orally ingested probiotic micro-organisms do not exert health effects exclusively in the intestine. Some strains can alleviate or prevent bacterial, fungal or viral infections in other organs by stimulation of the immune system. By preservation or improvement of the barrier function of the intestinal mucosa, they may inhibit translocation of potential pathogens and thus prevent infections of the blood stream and other tissues and organs. Modulation of the intestinal microflora can affect the local microflora of the urogenital tract and possibly of the oral cavity. Finally, some strains of orally ingested bacteria reach target organs like the urogenital tract in a viable state; alternatively they can be applied locally.

Despite the infection-preventing properties of probiotic bacteria, lactic acid bacteria have rarely been identified in infections of the blood stream, heart valves and other organs, usually only in patients with severe disease. It is the general opinion that in most cases the source of infection was the commensal microflora of the intestine or the oral cavity. Until now only one case of infection associated with administration of a probiotic strain has been published.

The most promising health-promoting effects have been seen in vaginosis, urinary tract infections, *Helicobacter pylori* gastritis and infections of the respiratory tract in children. More controlled clinical trials with sufficient numbers of participants are needed to determine the scientific basis for the use of probiotic bacteria in infections in locations of the body other than the intestine.

Probiotics: Non-intestinal infections

Introduction

Many of the widespread older definitions of the term 'probiotic', for example Fuller (1989): 'a live microbial feed supplement which beneficially affects the host (animal) by improving its intestinal microbial balance', confine probiotic effects to modulation of the microflora and/or immune system of the intestine. In contrast to this, the definition of Schrezenmeir & de Vrese (2001), namely 'a probiotic is a preparation or product containing viable, defined micro-organisms in sufficient numbers, which alters the microflora in a compartment of the host and by that exerts health effects in this host' emphasises that besides the intestine, other compartments of the body may be targets for probiotic micro-organisms, where an alteration of the microflora may exert health effects.

However, the 'natural' target of ingested probiotics is the intestine, its microflora and the associated immune system, and therefore investigations and clinical studies of non-intestinal infections are rather scarce. Possible applications for probiotics outside the intestine are bacterial and fungal infections of the oral cavity, the upper

respiratory tract and the lungs, the stomach and the urogenital tract. Common viral infections like the common cold or influenza are another target for probiotics. This would be of relevance to a large number of otherwise healthy subjects.

Urogenital tract infections

Bacterial and fungal infections of the urogenital tract are the most promising field of application for probiotics other than the intestine. Bacterial vaginosis, candida vaginitis and infections of the urethra, bladder, ureter, kidney or cervix affect 300 million women per year world-wide. They are due to microbial invasion or an imbalance of the urogenital microflora (Reid, 2001).

The flora of the vagina and the urinary tract consists of a well-balanced system of about fifty bacterial strains. Lactobacilli dominate the healthy flora of premenopausal women. They are believed to protect the host against infections by means of several mechanisms, including: (1) occupation of specific adhesion sites at the epithelial surface of

Abbreviations: Ig, immunoglobulin.

* Corresponding author: Dr M. de Vrese, fax +49 431 609 2472, email devrese@bafm.de

Table 1. Studies in vaginosis/vaginitis

Year	Study*	n	Probiotic	Application	Outcome	Reference
1975	O		Yoghurt	local	Non-specific vaginitis ↓, trichomonas vaginitis	Gunston & Fairbrother (1975)
1984	O, M	94	Lactobacilli tablets	oral	Pathogen symptoms ↓	Karkut (1984)
1992	X, P	21	<i>L. acidophilus</i> yoghurt	oral	Bacterial vaginosis – 87 %, candida vaginitis – 74 %	Hilton <i>et al.</i> (1992)
1992	R, P, dB	57	<i>L. acidophilus</i> (lyophilised)	local	Cure rate sixteen out of twenty-eight (probiotic) v. zero out of twenty-nine (placebo)	Hallen <i>et al.</i> (1992)
1995	O	11	Yoghurt	local	Symptoms ↓, pH ↓, eradication 54 %	Chimura <i>et al.</i> (1995)
1996	R, P, M	32	<i>L. acidophilus</i> (lyophilised) H ₂ O ₂ production	local	Cure-rate 88 % (probiotic) v. 22 % (placebo)	Parent <i>et al.</i> (1996)
1996	R, P, X	28	<i>L. acidophilus</i> yoghurt	oral	Episodes of bacterial vaginosis ↓	Shalev <i>et al.</i> (1996)
2001	O	10	<i>L. rhamnosus</i> , <i>L. fermentum</i> in milk	oral	Orally administered probiotics were identified in the vagina by molecular typing. Cure rate 60 %	Reid <i>et al.</i> (2001)

* Study type: O, open; R, randomised; P, placebo-controlled; dB, double-blind; X, cross-over design; M, multicentre.

the urinary tract; (2) stabilisation of a low pH and the production of antimicrobial substances like acids, hydrogen peroxide and bacteriocines; (3) the degradation of polyamines; and (4) the production of surfactants, which have anti-adhesive properties against the adhesion of pathogens (Reid, 2001). The balance can be disturbed by the overgrowth of indigenous bacteria of the vagina like *Gardnerella*, *Bacteroides*, *Peptostreptococcus*, *Prevotella* spp. or aerobic cocci, or by the invasion of foreign micro-organisms, such as *Escherichia coli*, *Enterococcus faecalis*, enterobacteriaceae, staphylococci or candida.

An obvious goal is to attempt to restore an unbalanced urogenital flora by adding protective 'probiotic' lactobacilli. Indeed, some efforts have been made to select lactobacilli strains that show the above protective properties to a high degree. Both pathogenic and probiotic micro-organisms may enter the urogenital tract by a variety of different routes. They come mainly from the colon and rectum via the perineum. However, when the immune system is stressed, translocation of gut bacteria through the intestinal wall is possible. Probiotic lactobacilli given orally can act via immunostimulation or inhibition of bacterial translocation. After entering the colon, they may alter the colonic microflora positively, and certain strains may reach the vagina and the urinary tract in a viable state (Reid *et al.* 2001). Alternatively, probiotics can be applied locally using appropriately treated tampons or gel beads, for example.

For many decades anecdotal reports rather than controlled studies have been published which show promising results of the oral or local application of yoghurt in vaginosis. However, studies showing eradication of pathogens, reduction of symptoms or fewer episodes of recurrent bacterial vaginosis were usually open, and the numbers of subjects were small (Table 1).

Comparable results were obtained in open and placebo-controlled studies, in which lyophilised *Lactobacillus acidophilus* was applied locally (Hallen *et al.* 1992; Parent *et al.* 1996) or *L. acidophilus* yoghurt was given orally (Hilton *et al.* 1992). In these studies success rates for bacterial vaginosis or candida-vaginitis ranged from 57 to 88 % in

the probiotic group and from 0 to 22 % in the control group. A rationale for the efficacy of orally ingested yoghurt was given by Reid and co-workers (2001), who proved using molecular typing that orally ingested probiotics reach the vagina in a viable state. Overall, more controlled clinical trials are needed to determine the scientific basis for the use of probiotic bacteria instead of or in conjunction with antibiotics in vaginosis and vaginitis.

Only a small number of human studies show positive health effects of probiotics in urinary tract infections (Table 2). Much of the work in this field was done by Reid and co-workers (2001). Since 1988 they have identified promising strains of *Lactobacillus rhamnosus*, *L. acidophilus* or *Lactobacillus fermentum*. These strains showed tight adhesion to epithelial surfaces, hydrogen peroxide production, or the release of biosurfactants. In a human study with forty-nine subjects, the local application of *L. rhamnosus* reduced the rate of urinary tract infections by 73 % (Reid & Bruce, 1995). This corresponds to *in vitro* and animal studies showing inhibitory effects of *L. acidophilus* and *L. rhamnosus* strains on growth and adhesion of some potentially pathogenic bacteria and *Candida* strains (Table 2). The possible importance of immunological mechanisms is underlined in a study where *Lactobacillus casei* Shirota inhibited the growth of *E. coli* and decreased inflammation in *E. coli*-infected mice, even when (the bacteria were) heat-killed (Asahara *et al.* 2001). More controlled clinical trials are needed.

Helicobacter pylori infections

The role of *Helicobacter pylori* in the aetiology of gastritis, gastric ulcer and gastric carcinomas and lymphomas is well established. More than 70 % of the ulcers of the gastric mucosa and duodenum are considered a consequence of *H. pylori* infection. Although it has been demonstrated that some strains of lactic acid bacteria inhibit the growth of *H. pylori* *in vitro* (Bhatia *et al.* 1989; Coconnier *et al.* 1998) and show adhesion to CaCo-2 cells (Brassart *et al.* 1993), results from investigations in gnotobiotic

Table 2. Studies in urinary tract infections

Year	Study/model*	n	Probiotic	Application	Outcome	Reference
1988	O	29	<i>B. longum</i>	oral	-70% candida infections in urethras (responders)	Tomoda <i>et al.</i> (1988)
1988	Screening			<i>in vitro</i>	Adhesiveness ↑, production of <i>E. coli</i> inhibitor ↓	McGroarty & Reid (1988)
1995	Epithelial cells		<i>L. acidophilus</i> , <i>L. rhamnosus</i>	<i>in vitro</i>	Adhesion of <i>C. albicans</i> ↓ and <i>S. aureus</i> ↓	Reid <i>et al.</i> (1995)
1995	O/R	49	<i>L. rhamnosus</i>	local	Urinary tract infection rate -73%	Reid & Bruce (1995)
1996	Screening		Fifteen strains of lactobacilli	<i>in vitro</i>	Biosurfactant production ↑; <i>E. faecalis</i> adhesion ↓	Velraeds <i>et al.</i> (1996)
1996	Mice†		<i>L. fermentum</i> in agarose beads	local	Moderately effective, <i>E. coli</i> ↓	Silva de Ruiz <i>et al.</i> (1996)
2001	Mice‡		(Heat-killed) <i>L. casei</i> Shirota	local	<i>E. coli</i> growth ↓, inflammation ↓	Asahara <i>et al.</i> (2001)

* Study type: O, open; R, randomised; P, placebo-controlled; dB, double-blind; X, cross-over design; M, multicentre.

† The urinary tract of the mice was infected with *E. coli*, and low-doses of ampicillin were given.

‡ The urinary tract of the mice was infected with *E. coli*.

mice (Kabir *et al.* 1997) and man have been somewhat surprising. Although, by definition, probiotics should reach the intestine to exert health effects — ingestion of *Lactobacillus salivarius*, *L. acidophilus* or *Lactobacillus johnsonii* prevented *H. pylori* infection, reduced the activity of *H. pylori* in the stomach and attenuated *H. pylori* gastritis (Table 3), indicating an effect on the stomach as well.

Helicobacter 'activity' is measured by means of the cleavage of the marker ¹³C-urea and the resulting increase in the ratio of ¹³CO₂ to ¹²CO₂ in the exhaled air. Human studies have shown that the outcome of the urea-breath test correlates significantly with mucosal concentrations of *H. pylori* (estimated from biopsies) or the degree of gastritis, respectively (correlation $r = 0.32$ and $r = 0.53$, respectively; Hilker *et al.* 1996). Perri *et al.* (1998) concluded that the urea-breath test is an appropriate measure to estimate both *H. pylori* concentration and gastritis.

Studies involving the effect of *L. acidophilus*, *L. rhamnosus* or *Bifidobacterium longum* on antibiotic-induced diarrhoea have been performed in *Helicobacter*-infected subjects during eradication therapy (de Vrese *et al.* 2001a). The ingestion of these probiotics as a yoghurt for four weeks significantly decreased *Helicobacter* activity even before *Helicobacter* eradication. This effect was independent of whether the probiotic bacteria were viable or

heat-killed (Fig. 1; de Vrese & Schrezenmeir, 2000a). This makes it probable that the effect on *Helicobacter* activity was caused by a component of the milk or the bacterial cell wall or by a fermentation product in the yoghurt.

Mouth and teeth

The microflora of the oral cavity is comprised of more than 100 bacterial species. The most prominent cariogenic bacterium is *Streptococcus mutans*, but many lactobacilli have cariogenic properties too. The composition of the oral microflora is influenced by bacterial transfer at birth, the gastrointestinal flora, the composition of the saliva and by other factors. The long-term composition is remarkably stable and does not vary with individual meals.

There are anecdotal reports of attempts to make the plaque flora on the teeth surface less cariogenic by adding harmless bacteria but no positive results of controlled studies have been published (Table 4a). In 1999 it was reported that lactobacilli from a bio-yoghurt colonised the surface of the teeth, increasing the cariogenicity of the plaque flora (Busscher *et al.* 1999). More promising are attempts to develop a vaccine against caries. Bayona Gonzalez and co-workers (1990) reported that the ingestion of heat-killed lactobacilli for six months reduced the incidence of caries by 42% during a two-year follow up.

Table 3. Effects of probiotics on *Helicobacter pylori* (Hp) activity and gastritis

Year	Study/model*	Probiotic	Outcome	Reference
1989	<i>in vitro</i>	<i>L. acidophilus</i>	Hp growth ↓	Bhatia <i>et al.</i> (1989)
1993	CaCo-2 cells	Preincubation with <i>L. johnsonii</i>	Hp adhesion to CaCo-2 cells ↓	Brassart <i>et al.</i> (1993)
1997	gnotobiotic mice	<i>L. salivarius</i>	Prevention of Hp infection and gastritis	Kabir <i>et al.</i> (1997)
1994	O, R, P	<i>L. acidophilus</i>	Hp activity (UBT) ↓	Bazzoli <i>et al.</i> (1994)
1998	O, n = 14	<i>L. acidophilus</i>	Six out of fourteen eradicated, Hp gastritis ↓	Mrda <i>et al.</i> (1998)
1999	R, P, n = 20	<i>L. johnsonii</i> culture supernatant	Hp activity ↓	Michetti <i>et al.</i> (1999)
2000	R, P, n = 72	<i>B. longum</i>	Hp activity ↓	de Vrese & Schrezenmeir (2000a)
2001	R, P	<i>L. johnsonii</i> fermented milk	Hp gastritis ↓	Felley <i>et al.</i> (2001)

* Study type: O, open; R, randomised; P, placebo-controlled.




Fig. 1. Effect of the consumption of fermented milk products on *Helicobacter pylori* activity in *Helicobacter*-positive subjects. Outcome of urea-breath tests (Delta over baseline (DOB) of $\Delta^{13}\text{CO}_2/^{12}\text{CO}_2$). Subjects consumed (placebo; ●—●; $n = 37$) pasteurised yoghurt without (placebo; ▲—▲; $n = 32$) or with *Bifidobacterium longum* BB 536 for eight weeks. *indicates a significant difference between day 0 and 28 within both dietary groups, Wilcoxon test (from de Vrese & Schrezenmeir, 2000a).

Respiratory tract infections

Very little is proven concerning the effects of probiotic bacteria in respiratory tract infections. It has been shown in animal experiments, when *Lactobacillus plantarum* and *Lactobacillus fermentum* were administered intranasally to mice, that the mucosa of the respiratory tract is an appropriate area for probiotics to induce immune stimulation. In clinical studies, ingestion of *Bifidobacterium longum* or yoghurt bacteria increased the number of macrophages in the

lungs, and administration of a bifidobacteria preparation to children with respiratory tract infections stimulated immunological parameters (Table 4b). However, it is not clear if and to what degree this immunostimulation led to attenuated or shorter infections (Lykova *et al.* 1996; Moineau & Goulet, 1997; Cangemi de Gutierrez *et al.* 2000; Grangette *et al.* 2001).

Miscellaneous infections

The use of probiotics in bacterial infections of other organs has been studied to a limited extent (Table 4c). Some authors have published open studies, in which the ingestion of probiotics reduced or enhanced *Candida* concentrations in liver, spleen and the lungs or inhibited translocation of pathogenic bacteria from the intestine into internal organs in subjects with a sub-optimal immune system (Tomoda *et al.* 1988).

An unusual finding is that the administration of *Lactobacillus casei* to *Trichinella*-infected mice increased interferon gamma and decreased significantly the number of trichinae in the muscles. This was due to an eradication of the adult trichinae in the intestine due to immunostimulation (Bautista-Garfias *et al.* 1999).

Common viral infections

The mechanisms by which probiotics exert effects against viral infections is considered to be by immunostimulation and not by direct competition with the infectious agent in the gut. Therefore, probiotics with proven immunostimulatory properties may be appropriate candidates for the prevention or treatment of viral infections. This has been investigated in rotavirus infections and also for viruses whose target organ is not the intestine. Examples include polio, hepatitis and the group of viruses involved in common viral diseases (Table 5).

The effect of orally administered strains of *L. rhamnosus*

Table 4. Studies in infections of the oral cavity, the upper respiratory tract and others

Year	Study/model*	Probiotic	Outcome	Reference
(a) Mouth and teeth				
1990	Anectotal R, P, 245 children	appropriate strains Heat-killed Lb. for 16 weeks	Modulation of the mouth flora 2-year follow up: caries – 42%	Bayona Gonzalez <i>et al.</i> (1990)
1999	<i>in vivo</i>	Lactobacilli from a bio-yoghurt	Colonisation of tooth surface	Busscher <i>et al.</i> (1999)
(b) Respiratory tract infections				
1997	R, P	<i>B. longum</i> , yoghurt bacteria	Lung macrophages ↑	Moineau & Goulet (1997)
2000	129 children with acute RTI	10^9 cfu/ml Bifidum-bacterin forte	T/B-cell immunity ↑, NK-cells ↑, interferon ↑; infection-resistance ↑	Lykova <i>et al.</i> (1996)
2000	mice	<i>L. fermentum</i>	Immune stimulation; specific humoral and mucosal antibodies ↑	Cangemi de Gutierrez <i>et al.</i> (2000)
2001	mice	<i>L. plantarum</i> intra-nasal	(Activated) lung macrophages ↑	Grangette <i>et al.</i> (2001)
(c) Miscellaneous infections				
1988	O, $n = 29$	<i>B. longum</i> (oral)	In responders: – 70% candida 'infections' in lungs, liver, spleen	Tomoda <i>et al.</i> (1988)
1999	<i>Trichinella</i> -infected mice	<i>L. casei</i>	Larvae/g muscle: – 47–84%; IFN-gamma ↑ adult worms (intestine): – 80%	Bautista-Garfias <i>et al.</i> (1999)

* Study type: O, open; R, randomized; P, placebo-controlled.

Table 5. Probiotics in virus infections

Year	Study*	Probiotic	Application	Outcome	Reference
1999	mice	<i>B. breve</i>	oral	Anti-rotavirus IgA ↑, anti-Influenza IgG ↑. Protection against RV/influenza infection?	Yasui <i>et al.</i> (1999)
2001	R, P; oral polio vaccination	<i>L. rhamnosus</i> , <i>L. paracasei</i>	oral (yoghurt)	Anti-polio IgA ↑, anti-polio IgG ↑, neutralising antibodies ↑	de Vrese <i>et al.</i> (2001 <i>b</i>)
2000	R, P; hepatitis A & B vaccination	<i>L. acidophilus</i> , <i>B. bifidum</i>	oral (lyophilisate)	NS	de Vrese & Schrezenmeir (2000 <i>b</i>)
2001	R, P – 371 healthy children	<i>L. rhamnosus</i> for seven months	oral	– 17% respiratory tract-infected children; 4.9 days of illness (control) v. 5.8 days (placebo)	Hatakka <i>et al.</i> (2001)

* Study type: R, randomized, P, placebo-controlled.

and *L. paracasei* during oral infection with an enterovirus, namely polio I, II and III, was investigated in a randomised, double-blind, placebo-controlled clinical study (de Vrese *et al.* 2001*b*). For this purpose sixty-six subjects in three groups ingested one of two probiotic yoghurt products or a chemically acidified milk product as the placebo for 8 weeks. One week after the beginning of the yoghurt period, the subjects were vaccinated orally with live attenuated polioviruses. Ingestion of both probiotic yoghurts enhanced significantly the vaccination-induced increase in polio virus-neutralising antibody concentration in serum. Neutralising antibody titres — mainly immunoglobulin (Ig)A — were measured as the potency of a stepwise diluted serum to protect cultured cells against a lethal poliovirus infection.

The increase in polio-specific IgG and IgA in serum after vaccination was also significantly enhanced by factors of about 2.2 or 4, respectively, in volunteers consuming probiotic yoghurts compared with placebo. The study showed that probiotics induce an immunological response and provide protection from polioviruses by increased production of virus-neutralising antibodies.

The evidence that the consumption of certain probiotics can reduce the risk of some common viral infections like the common cold or influenza would be of great interest because a great number of otherwise healthy subjects regularly suffer from common virus diseases. The first evidence that some probiotic strains could be effective in this way came from experiments in influenza (and rotavirus) infected mice. In the group that received a probiotic strain of *Bifidobacterium breve* more mice had

anti-influenza-IgG concentrations above 400 U and had a higher survival rate (Yasui *et al.* 1999). The first controlled study which showed that long-term consumption of probiotic bacteria had positive effects on common gastrointestinal and respiratory tract infections in an otherwise healthy population was performed in Finland. Three hundred and seventy-one children (aged 1–6 years) from day-care centres consumed milk with or without the probiotic *L. rhamnosus* strain daily for seven months. In the probiotic group fewer children had respiratory tract infections (17% reduction compared to the placebo group). These children also had fewer days away from the centres because of gastrointestinal and respiratory tract illnesses (4.9 versus 5.8 days) and needed less antibiotic administration. However no differentiation was made in the study between viral and microbial infections (Hatakka *et al.* 2001).

Infectivity of probiotic bacteria

With one exception no probiotic micro-organisms have been identified in isolates from clinical infections. Therefore the rest of this section deals with the infectivity of lactobacilli and bifidobacteria in general.

Lactobacilli and bifidobacteria, which include most of the probiotic micro-organisms used in the food industry, are generally considered safe because they are common components of the commensal microflora of humans and many lactic acid bacteria have a long history of consumption without harmful effects. In Germany, for example, lactobacilli and bifidobacteria are assigned to risk group 1 — no

Table 6. Infectivity of lactic acid bacteria and yeasts

Authors	Strain	Isolated from	Frequency
Oakey <i>et al.</i> (1995)	Lb spp., Sc spp. (eF)	Endocarditis	
Brook & Frazier (1993)	Bb spp., Lb spp. (eF)	Abdominal abscesses	< 0.6%
Saxelin <i>et al.</i> (1996)	<i>L. casei</i> (LGG)	Blood cultures	0.24%
Adams (1999)	<i>L. rhamnosus</i> , <i>casei</i> , <i>L. reuteri</i> , <i>L. acidophilus</i> (kP)	Infections*	
Adams (1999)	Ec spp.	Endocarditis	2%
Rogasi <i>et al.</i> (1998)	<i>L. casei</i>	Pneumonia and sepsis*	
Piarroux <i>et al.</i> (1999)	<i>Saccharomyces boulardii</i> (sometimes a wrongly identified <i>S. cerevisiae</i>)	Fungemia	1.6%
Rautio <i>et al.</i> (1999)	<i>L. rhamnosus</i> (undistinguishable from LGG)	Liver abscesses	One case

Bb, *Bifidobacterium*; L, *Lactobacillus*; Sc, *Streptococcus*; Ec, *Enterococcus*; eF, from the endogenous intestinal flora; nP, no probiotics.

*Immunodeficient subjects.

health risk — by the 'Professional Association of the Chemical Industry' (Berufsgenossenschaft der Chemischen Industrie, 1997). Only *L. rhamnosus* strains and *Bifidobacterium dentium* are placed in group 2 — small risk. Although lactobacilli, bifidobacteria or the probiotic yeast *Saccharomyces boulardii* have been identified in infections of the blood stream (bacteraemia), heart valves (infectious endocarditis), the cerebral membrane (meningitis), the urinary tract, the liver and other organs (Aguirre & Collins, 1993; Oakey *et al.* 1995; Adams, 1998; Rogasi *et al.* 1998; Piarroux *et al.* 1999), infections by lactobacilli, lactococci and bifidobacteria, especially those strains which include food probiotics, are rare. Examples are given in Table 6. Gasser (1994) reported that lactic acid bacteria accounted for 0.05–0.4% of cases of infective endocarditis, whereas streptococci and staphylococci accounted for nearly 80%. Among 3317 blood culture isolates from southern Finland analysed between 1989 and 1992 (Saxelin *et al.* 1996) lactobacilli were identified in only eight samples. This was equivalent to a prevalence of lactobacilli-induced bloodstream infections of 0.24%; in France, 0.1% of cases of bacteraemia were caused by *Lactobacilli* (Gasser, 1994).

A prerequisite of lactic acid bacteria infection is impaired host health. These infections are probably opportunistic infections, e.g. due to skin lesions or injuries of internal organs. For example, the starting point of infectious endocarditis is frequently a (transient) bacteraemia caused by micro-organisms from the oral cavity, which entered the blood stream through lesions of the oral mucosa or following dental surgery. Bacterial translocation through the intestinal mucosa and subsequent invasion via mesenteric lymph nodes or the portal vein also plays an important role in bacteraemia, which may progress to septicaemia and infections of other inner organs. Translocation is promoted by many conditions which decrease the intestinal barrier: injuries of the intestinal mucosa, infections or inflammatory diseases of the gut, abdominal surgery, intestinal bacterial overgrowth, massive antibiotic treatment and/or host immunodeficiency, i.e. after chemotherapy, radiation or in HIV-infected patients. There is no proven difference between the commensal microflora of the host and (probiotic) lactic acid bacteria administered orally with respect to the above mechanisms. However, it is still unclear to what extent orally ingested bacteria and food probiotics actually translocate, particularly as most of the existing studies have not recorded the dietary habits of the patients.

Investigations in germ-free mice have shown that after oral mono-association of the mice with a probiotic *Bifidobacterium longum* strain, bifidobacteria translocated and were found in the mesenteric lymph nodes, liver and kidneys one week later. Translocation of probiotic bacteria had no harmful effects but increased the barrier function of the intestinal mucosa and inhibited translocation of the other bacteria. After a latency period of 4 weeks no further bacterial translocation was observed, neither of *B. longum* nor of other (potentially pathogenic) bacteria administered to the mice (Yamazaki *et al.* 1982).

In most cases the source of clinical infections by lactobacilli and bifidobacteria is thought to be the commensal microflora of the intestine or the oral cavity, and not

orally ingested probiotic micro-organisms. To confirm this, the identification of specific strains by molecular biological methods is required. Until now only one case of a probiotic infection has been published, which probably was caused by probiotic lactobacilli. This was in 1999, when Rautio and colleagues isolated a *L. rhamnosus* strain from a liver abscess that was indistinguishable from the probiotic *L. rhamnosus* strain GG (Rautio *et al.* 1999).

Comparing the scarcity of infections by lactobacilli and bifidobacteria with the quantity of probiotic ingested, probiotic lactobacilli and bifidobacteria can be regarded as safe. There is no indication that reduced consumption of probiotic bacteria would decrease the number of such infections.

References

- Adams MR (1998) Safety of industrial lactic acid bacteria. *Journal of Biotechnology* **68**, 171–178.
- Aguirre M & Collins MD (1993) Lactic acid bacteria and human clinical infection. *Journal of Applied Bacteriology* **75**, 95–107.
- Asahara T, Nomoto K, Watanuki M & Yokokura T (2001) Antimicrobial activity of intraurethraly administered probiotic *Lactobacillus casei* in a murine model of *Escherichia coli* urinary tract infection. *Antimicrobial Agents and Chemotherapy Journal* **45**, 1751–1760.
- Bautista-Garfias CR, Ixta O, Orduna M, Martinez F, Aguilar B & Cortes A (1999) Enhancement of resistance in mice treated with *Lactobacillus casei*: effect on *Trichinella spiralis* infection. *Veterinary Parasitology* **14**, 251–260.
- Bayona Gonzalez A, Lopez Camara V & Gomez Castellanos A (1990) Prevencion de caries por lactobacilos (resultados finales de un ensayo clinico sobre caries dental con lactobacilos muertos [estreptococos y lactobacilos] por via oral) (Prevention of caries with lactobacillus (final results of a clinical trial on dental caries with killed lactobacillus [streptococcus and lactobacillus] given orally)). *Practica Odontologica* **11**, 37–39.
- Bazzoli F, Zagari RM, Pozzato P, Fossi S, Alampi G, Scottili S, Simoni P, Roda A & Roda E (1994) 13C-Urea-breath-test to quantify *Helicobacter pylori* colonization of gastric mucosa and association with severity of inflammation. *Gastroenterology* **106**, A48.
- Berufsgenossenschaft der Chemischen Industrie (1997) Eingruppierung biologischer Agenzien: Bakterien. Sichere Biotechnologie, Merkblatt B006, 2/97.
- Bhatia SJ, Kochar N, Abraham P, Nair NG & Mehta AP (1989) *Lactobacillus acidophilus* inhibits growth of *Campylobacter pylori* *in vitro*. *Journal of Clinical Microbiology* **27**, 2328–2330.
- Brassart D, Bernet M-F, Michetti P, Neeser J-R & Servin AL (1993) Adhesion of dairy lactobacilli and bifidobacteria to the human differentiated enterocytic cell lines HT-29 and Caco-2 and protection against gastrointestinal pathogens. First World Congress of Dairy Products in Human Health and Nutrition, Madrid, 7–10 June 1993. Abstract 106.
- Brook I & Frazier EH (1993) Significant recovery of nonsporulating anaerobic rods from clinical specimens. *Clinical Infectious Diseases* **16**, 476–480.
- Busscher HJ, Mulder AF & van der Mei HC (1999) *In vitro* adhesion to enamel and *in vivo* colonization of tooth surfaces by Lactobacilli from a bioyoghurt. *Caries Research* **33**, 403–404.
- Cangemi de Gutierrez RC, Santos de Araoz VS & Nader-Macias ME (2000) Effect of intranasal administration of *Lactobacillus*

- fermentum* on the respiratory tract of mice. *Biological and Pharmaceutical Bulletin* **23**, 973–978.
- Chimura T, Funayama T, Murayama K & Numazaki M (1995) Ecological treatment of bacterial vaginosis. *Japanese Journal of Antibiotics* **48**, 432–436.
- Coconnier MH, Lievin V, Hemery E & Servin AL (1998) Antagonistic activity against *Helicobacter* infection *in vitro* and *in vivo* by the human *Lactobacillus acidophilus* strain LB. *Applied Environmental Microbiology* **64**, 4573–4580.
- de Vrese M, Fenselau S, Feindt F, Laue C, Kristen H, Lick S, Heller K, Schrezenmeir J, Plock J, Kleinbach-Sauter H, Ishibashi N, Hayasawa H & Tomita M (2001a) Effects of yogurt containing *Bifidobacterium longum* BB536 on diarrhea induced by antibiotic administration for eradication of *H pylori*. Conference of Intestinal Bacteriology (ICIB), Tokyo, 5 June.
- de Vrese M, Rautenberg P, Laue C, Koopmans M, Herremans T & Schrezenmeir J (2001b) Einfluss von Probiotika auf die Immunantwort auf eine Polioschluckimpfung (Effects of probiotics on immune response to polio vaccination). *Proceedings of the German Nutrition Society* **3**, 7.
- de Vrese M & Schrezenmeir J (2000a) Einfluß probiotischer Bifidobakterien auf die *Helicobacter pylori* activity (Effects of probiotic bifidobacteria on *Helicobacter* activity). *Annual Report 2000*, p. 58. Kiel: Federal Dairy Centre.
- de Vrese M & Schrezenmeir J (2000b) Einflüsse von Probiotika auf die Immunantwort auf eine Hepatitis A und B-Impfung (Effects of probiotics on a defined immunological challenge with Hepatitis A and B vaccine). *Annual Report 2000*, p. 57. Kiel: Federal Dairy Centre.
- Felley CP, Corthesy-Theulaz I, Rivero JLB, Sipponen P, Kaufmann M, Bauerfeind P, Wiesel PH, Brassart D, Pfeifer A, Blum AL & Michetti P (2001) Favourable effects of an acidified milk (LC-1) on *Helicobacter pylori* gastritis in man. *European Journal of Gastroenterology and Hepatology* **13**, 25–29.
- Fuller R (1989) Probiotics in man and animals. *Journal of Applied Bacteriology* **66**, 365–378.
- Gasser F (1994) Safety of lactic acid bacteria and their occurrence in human clinical infections. *Bulletin de l'Institut Pasteur* **92**, 45–67.
- Grangette C, Muller-Alouf H, Goudercourt D, Geoffroy MC, Turneer M & Mercenier A (2001) Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant *Lactobacillus plantarum*. *Infection and Immunity* **69**, 1547–1553.
- Gunston KD & Fairbrother PF (1975) Treatment of vaginal discharge with yoghurt. *South African Medical Journal* **49**, 675–676.
- Hallen A, Jarstrand C & Pahlson C (1992) Treatment of bacterial vaginosis with lactobacilli. *Sexually Transmitted Diseases* **19**, 146–148.
- Hatakka K, Savilahti E, Ponka A, Meurman JH, Poussa T, Nase L, Saxelin M & Korpela R (2001) Effect of long term consumption of probiotic milk on infections in children attending day care centres: double-blind, randomised trial. *British Medical Journal* **322**, 1327–1329.
- Hilker E, Stoll R & Domschke W (1996) 13C-urea breath test for detection of *Helicobacter pylori* and its correlation with endoscopic and histologic findings. *Journal of Physiology and Pharmacology* **47**, 79–90.
- Hilton E, Isenberg HD, Alperstein P, France K & Borenstein MT (1992) Ingestion of yoghurt containing *Lactobacillus acidophilus* as prophylaxis for *Candidal* vaginitis. *Annals of Internal Medicine* **116**, 353–357.
- Kabir AMA, Aiba Y, Takagi A, Kamiya S, Miwa T & Koga Y (1997) Prevention of *Helicobacter pylori* infection by *lactobacilli* in a gnotobiotic murine model. *Gut* **41**, 49–55.
- Karkut G (1984) Wirkung einer Lactobazillus-Immuntherapie auf die Genitalinfektion der Frau (Solco Trichovac/Gynatren) (Effect of lactobacillus immunotherapy on genital infections in women (Solco Trichovac/Gynatren)). *Geburtshilfe Frauenheilkunde* **44**, 311–314.
- Lykova EA, Vorob'ev AA, Bokovoi AG, Pobedinskaia IN, Gevondian VS & Gevondian NM (1996) Effect of lactobacilli and antibiotics on *E. coli* urinary infections in mice. *Biological and Pharmaceutical Bulletin* **191**, 88–93.
- McGroarty JA & Reid G (1988) Detection of a lactobacillus substance that inhibits *Escherichia coli*. *Canadian Journal of Microbiology* **34**, 974–978.
- Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M, Felley C, Porta N, Rouvet M, Blum AL & Corthesy-Theulaz I (1999) Effect of whey-based culture supernatant of *Lactobacillus acidophilus* (*johnsonii*) La 1 on *Helicobacter pylori* infection in humans. *Digestion* **60**, 203–209.
- Moineau S & Goulet J (1997) Effect of feeding fermented milks on the pulmonary macrophage activity in mice. *Milchwissenschaft* **46**, 551–554.
- Mrda Z, Zivanovic M, Rasic J, Gajin S, Somer L, Trbojevic S, Majoros J & Petrovic Z (1998) Terapija *Helicobacter pylori* infekcije primenom *Lactobacillus acidophilus* (Therapy of *Helicobacter pylori* infection using *Lactobacillus acidophilus*). *Meditsinski Pregled* **51**, 343–345.
- Oakey HJ, Harry DWS & Knox KW (1995) Enzyme production by lactobacilli and the potential link with endocarditis. *Journal of Applied Bacteriology* **78**, 142–148.
- Parent D, Bossens M, Bayot D, Kirkpatrick C, Graf F, Wilkinson FE & Kaiser RR (1996) Therapy of bacterial vaginosis using exogenously-applied *Lactobacilli acidophilii* and a low dose of estriol: a placebo-controlled multicentric clinical trial. *Arzneimittelforschung* **46**, 68–73.
- Perri F, Clemente R, Pastore M, Quitadamo M, Festa V, Bisceglia M, Li Bergoli M, Lauriola G, Leandro G, Ghos Y, Rutgeerts P & Andriulli A (1998) The 13C-urea breath test as a predictor of intragastric bacterial load and severity of *Helicobacter pylori* gastritis. *Scandinavian Journal of Clinical and Laboratory Investigations* **58**, 19–27.
- Piarroux R, Millon L, Bardonnnet K, Vagner O & Koenig H (1999) Are live saccharomyces yeasts harmful to patients? *Lancet* **353**, 1851–1852.
- Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkyinen S & Koskela M (1999) Liver abscess due to a *Lactobacillus rhamnosus* strain indistinguishable from *L. rhamnosus* strain GG. *Clinical Infectious Diseases* **28**, 1159–1160.
- Reid G (2001) Probiotic agents to protect the urogenital tract against infection. *American Journal of Clinical Nutrition* **73**, Suppl. 2, 437S–444S.
- Reid G & Bruce AW (1995) Low vaginal pH and urinary-tract infection. *Lancet* **346**, 1704.
- Reid G, Bruce AW, Fraser N, Heinemann C, Owen J & Henning B (2001) Oral probiotics can resolve urogenital infections. *FEMS Immunology and Medical Microbiology* **30**, 49–52.
- Reid G, Tieszer C & Lam D (1995) Influence of lactobacilli on the adhesion of *Staphylococcus aureus* and *Candida albicans* to fibers and epithelial cells. *Journal of Industrial Microbiology* **15**, 248–253.
- Rogasi PG, Vigano S, Pecile P & Leoncini F (1998) *Lactobacillus casei* pneumonia and sepsis in a patient with AIDS. Case report and review of the literature. *Annali Italiani de Medicina Interna* **13**, 180–182.
- Saxelin M, Chuang NH, Chassy B, Rautelin H, Salminen S & Gorbach SL (1996) Lactobacilli and bacteremia in Southern Finland, 1989–1992. *Clinical Infectious Diseases* **22**, 564–566.
- Schrezenmeir J & de Vrese M (2001) Probiotics, prebiotics, and

- synbiotics — approaching a definition. *American Journal of Clinical Nutrition* **73**, Suppl, 361S–364S.
- Shalev E, Battino S, Weiner E, Colodner R & Keness Y (1996) Ingestion of yoghurt containing *Lactobacillus acidophilus* compared with pasteurized yoghurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. *Archives of Family Medicine* **5**, 593–596.
- Silva de Ruiz C, Lopez de Bocanera ME, Nader de Macias ME & Pesce de Ruiz Holgado AA (1996) Effect of lactobacilli and antibiotics on *E. coli* urinary infections in mice. *Biological & Pharmaceutical Bulletin* **19**, 88–93.
- Tomoda T, Nakano Y & Kageyama T (1988) Intestinal *Candida* overgrowth and *Candida* infection in patients with leukemia: effect of *Bifidobacterium* administration. *Bifidobacteria and Microflora* **7**, 71–74.
- Velraeds MM, van der Mei HC, Reid G & Busscher HJ (1996) Inhibition of initial adhesion of uropathogenic *Enterococcus faecalis* by biosurfactants from *Lactobacillus* isolates. *Applied and Environmental Microbiology* **62**, 1958–1963.
- Yamazaki S, Kamimura H, Momose H, Kawashima T & Ueda K (1982) Protective effect of *Bifidobacterium*-monoassociation against lethal activities of *Escherichia coli*. *Bifidobacteria and Microflora* **1**, 55–59.
- Yasui H, Shida K, Matsuzaki T & Yokokura T (1999) Immunomodulatory function of lactic acid bacteria. *Antonie Van Leeuwenhoek* **76**, 383–389.